New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose
US FDA approved crinecerfont (Crenessity) for congenital adrenal hyperplasia (CAH) in adults and children aged 4+; first new therapy for CAH in 70 years. Indicated as adjunctive treatment to glucocorticoid replacement therapy, it reduces excess adrenal androgens. Based on phase 3 CAHtalyst trial data.
Highlighted Terms
Related News
New Treatment Approved for Congenital Adrenal Hyperplasia: Daily Dose
US FDA approved crinecerfont (Crenessity) for congenital adrenal hyperplasia (CAH) in adults and children aged 4+; first new therapy for CAH in 70 years. Indicated as adjunctive treatment to glucocorticoid replacement therapy, it reduces excess adrenal androgens. Based on phase 3 CAHtalyst trial data.